A Phase 3 interventional study of Ferric Carboxymaltose (FCM) and Ferrous Sulfate tablets in Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-20.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.
Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 12th largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 4th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:
Biocruces Bizkaia Health Research Institute · Sites in Spain
Ages 18+
Children's Hospital of Orange County
Ages 1–18
Helsinki University Central Hospital
Ages 18+
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 24 · Phase 4 23
First in 2005; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 456 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 156 across the 54 interventional studies. Of the 45 that completed or were terminated, 13 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under American Regent, Inc., one of the names counted as Daiichi Sankyo. Under that name alone:
American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
19 studies in Anemia by Daiichi Sankyo: none open now, none under way, none of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 19 studies in Anemia by Daiichi Sankyo, this one is the 6th largest by enrollment, is one of 6 that started in 2005, is one of 15 in phase 3, and was the 10th registered.
Daiichi Sankyo’s Anemia studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing ferric carboxymaltose in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daiichi Sankyo’s 19 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compares of the safety and efficacy of intravenous iron vs oral iron in the treatment of anemia secondary to heavy uterine bleeding
This is an open-label, randomized, Phase III, active-control, study of the efficacy and safety of IV iron vs oral iron in patients with anemia secondary to heavy uterine bleeding.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
Drug: Ferric Carboxymaltose (FCM)
325 mg tablets TID on Days 0 through Day 42
Drug: Ferrous Sulfate tablets
Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
325 mg tablets TID on Days 0 through Day 42
Also known as: Oral Iron Tablets
Number of Subjects Achieving 'Clinical Success'. Clinical Success is Defined as an Increase in Hemoglobin of ≥ 2.0 g/dL
Time frame: Any time between baseline and the end of study or time to intervention
Hospitals and medical clinics
| Milestone | Ferric Carboxymaltose (FCM) | Oral Iron Tablets |
|---|---|---|
| Started | 246 | 231 |
| Completed | 211 | 212 |
| Not completed | 35 | 19 |
| participants | Ferric Carboxymaltose (FCM) | Oral Iron Tablets |
|---|---|---|
| Number of Subjects Achieving 'Clinical Success'. Clinical Success is Defined as an Increase in Hemoglobin of ≥ 2.0 g/dL | 187 | 139 |
Collected over 11 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ferric Carboxymaltose (FCM) | — | 3/230 (1.3%) | 120/230 (52.2%) |
| Oral Iron Tablets | — | 3/226 (1.3%) | 133/226 (58.8%) |
| Event | Ferric Carboxymaltose (FCM) | Oral Iron Tablets |
|---|---|---|
| Uterine hemorrhageReproductive system and breast disorders | 1/230 | 1/226 |
| Transient ischemic attackNervous system disorders | 0/230 | 1/226 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/230 | 1/226 |
| Abdominal painGastrointestinal disorders | 0/230 | 1/226 |
| Chest painGeneral disorders | 1/230 | 0/226 |
| Pelvic inflammatory diseaseInfections and infestations | 1/230 | 0/226 |
| Event | Ferric Carboxymaltose (FCM) | Oral Iron Tablets |
|---|---|---|
| ConstipationGastrointestinal disorders | 8/230 | 35/226 |
| HeadacheNervous system disorders | 34/230 | 27/226 |
| NauseaGastrointestinal disorders | 12/230 | 33/226 |
| Blood phosphorus decreasedRenal and urinary disorders | 26/230 | 0/226 |
| NasopharyngitisInfections and infestations | 7/230 | 14/226 |
| DiarrheaGastrointestinal disorders | 8/230 | 13/226 |
| FatigueGeneral disorders | 13/230 | 5/226 |
| Abdominal painGastrointestinal disorders | 12/230 | 6/226 |
16 of the 246 subjects randomized to FCM were discontinued prior to dosing and 5 of the 231 subjects randomized to oral iron were discontinued prior to dosing.
| Age, Categorical(Participants) | Ferric Carboxymaltose (FCM) | Oral Iron Tablets | Total |
|---|---|---|---|
| <=18 years | 2 | 0 | 2 |
| Between 18 and 65 years | 228 | 226 | 454 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Ferric Carboxymaltose (FCM) | Oral Iron Tablets | Total |
|---|---|---|---|
| Mean | 38.7 ± 7.49 | 39.5 ± 7.63 | 39.1 ± 7.54 |
| Sex: Female, Male(Participants) | Ferric Carboxymaltose (FCM) | Oral Iron Tablets | Total |
|---|---|---|---|
| Female | 230 | 226 | 456 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | Ferric Carboxymaltose (FCM) | Oral Iron Tablets | Total |
|---|---|---|---|
| United States | 230 | 226 | 456 |
The record gives a start of May 2005, a primary completion of Apr 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 7 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose